Drugs / SNA02-48
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06939777 | Apr → Dec 2025 | tetanus | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07633119 | Jun 2026 → Mar 2027 expected | tetanus | Sinovac Life Sciences Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNA02-48 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07633119 ↗ |
| Modality | Monoclonal antibody | “full human anti-tetanus toxin monoclonal antibody SNA02-48 injection” NCT06939777 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT06939777 ↗ |